Becker's Hospital Review - Cardiology
SEPTEMBER 19, 2024
Renton, Wash.-based Providence is planning a $42 million renovation of the Providence Heart Institute in Spokane, which will increase its patient capacity by 15%, according to a Sept. 17 report from the Spokane Journal of Business.
HCPLive
SEPTEMBER 19, 2024
In this segment of his interview, Zirwas highlighted the use of JAK inhibitors such as upadacitinib, discussed safety, and touched on topical options for patients with eczema.
Becker's Hospital Review - Cardiology
SEPTEMBER 19, 2024
"Stay updated on the latest findings in cardiology, including the use of machine-learning models and genetic testing to improve patient care and outcomes.
HCPLive
SEPTEMBER 19, 2024
The FDA declined to approve the NDA for tradipitant for the treatment of symptoms of gastroparesis, suggesting that Vanda conduct additional studies.
Open Heart
SEPTEMBER 19, 2024
Background The value of empirical superior vena cava isolation (SVCI) following pulmonary vein isolation (PVI) to improve the efficacy of radiofrequency catheter ablation (RFCA) for paroxysmal atrial fibrillation (PAF) remains controversial. Objective To evaluate the efficacy and safety of quantitative ablation index (AI)-guided empirical SVCI, in addition to PVI, for patients with PAF.
Becker's Hospital Review - Cardiology
SEPTEMBER 19, 2024
A pharmaceutical gene therapy has shown promise in treating calmodulinopathy, a rare and hard-to-treat heart arrhythmia, according to a study published Aug. 19 in Circulation.
Open Heart
SEPTEMBER 19, 2024
Background Inflammation plays a pivotal role in atherogenesis and is a causal risk factor for atherosclerotic cardiovascular disease. Non-invasive coronary CT angiography (CCTA) enables evaluation of coronary plaque phenotype. This study investigates the relationship between a comprehensive panel of inflammatory markers and short-term plaque progression on serial CCTA imaging, hypothesising that inflammation is associated with increased plaque volume.
Cardiovascular Update brings together the best content for cardiovascular medicine professionals from the widest variety of industry thought leaders.
DAIC
SEPTEMBER 19, 2024
tim.hodson Thu, 09/19/2024 - 09:42 Sept. 18, 2024 – Astellas Pharma Inc. recently announced that Digitiva, a non-invasive digital health solution for heart failure management, has been listed with the U.S. Food and Drug Administration (FDA). Digitiva is classified as a Class I Software as a Medical Device (SaMD) and is exempt from 510(k) premarket submission*.
Cardiometabolic Health Congress
SEPTEMBER 19, 2024
The U.S. Food and Drug Administration (FDA) has approved Eversense 365, the first and only continuous glucose monitoring (CGM) system designed to function for an entire year, according to a company press release. Developed by Senseonics and Ascensia Diabetes Care, the device represents a significant advancement in long-term glucose monitoring technology.
HCPLive
SEPTEMBER 19, 2024
Panelists discuss how switching to a biologic with a different mechanism of action can enhance clinical outcomes in patients with inadequate responses to tumor necrosis factor inhibitors.
American College of Cardiology
SEPTEMBER 19, 2024
The goal of the Iberis-HTN trial was to assess the efficacy and safety of the multi-electrode, unipolar AngioCare Iberis renal denervation (RDN) system in patients with treatment-resistant primary hypertension (HTN) on a standardized three-drug regimen.
HCPLive
SEPTEMBER 19, 2024
Panelists discuss how continued cycling of tumor necrosis factor inhibitors (TNFis) without achieving remission can lead to complications like irreversible joint erosion, significantly diminishing patient quality of life, and explore why providers may persist with TNFis despite failure, access barriers to switching mechanisms of action, and treatment considerations for patients whose initial positive response to TNFis declines over time.
American College of Cardiology
SEPTEMBER 19, 2024
The following are key points to remember from a state-of-the-art review on the established and emerging therapeutic role of mineralocorticoid antagonism in patients with heart failure (HF).
HCPLive
SEPTEMBER 19, 2024
High-risk SAFE scores were linked to increased mortality, especially in participants with alcohol-associated liver disease, as this group demonstrated the worst survival.
American College of Cardiology
SEPTEMBER 19, 2024
Is coronary artery calcium (CAC) density by computed tomography (CT) inversely associated with plaque vulnerability and atherosclerotic cardiovascular disease (ASCVD) events (coronary heart disease [CHD] and stroke)?
HCPLive
SEPTEMBER 19, 2024
Positive topline results from the phase 2a HERALD study of ALG-055009 in MASH highlight the THR-β agonist’s impact on liver fat reduction.
American College of Cardiology
SEPTEMBER 19, 2024
How do patient-level factors, including race/ethnicity and county-level socioeconomic status (SES) affect inequities in prehospital care of patients with stroke?
HCPLive
SEPTEMBER 19, 2024
Shapiro spoke in his Maui Derm NP+PA Fall conference interview about differentiating between types of alopecia areata and about the potential use of JAK inhibitors.
HCPLive
SEPTEMBER 19, 2024
Lp(a) ordering remains low in patients at risk for ASCVD, particularly non-Hispanic Black or Hispanic individuals in socioeconomically disadvantaged neighborhoods.
HCPLive
SEPTEMBER 19, 2024
This interview with Culton featured a discussion of key challenges faced when treating patients with blistering diseases such as pemphigus and bullous pemphigoid.
HCPLive
SEPTEMBER 19, 2024
EDG-7500 was well-tolerated in healthy patients in Phase 1 while achieving gradient relief without LVEF reductions in the Phase 2 CIRRUS-HCM trial.
HCPLive
SEPTEMBER 19, 2024
A study revealed erenumab at 140 mg is effective and safe in achieving remission of headaches caused by non-opioid medication overuse.
HCPLive
SEPTEMBER 19, 2024
Digital ACT demonstrated superiority over active control in a number of outcomes in a phase 3 trial.
HCPLive
SEPTEMBER 19, 2024
The increase will largely be driven by population growth and aging.
HCPLive
SEPTEMBER 19, 2024
The model Revised REACH-B outperforms an earlier model by incorporating predictors of predictors of age, sex, platelet count, ALT levels, and positive hepatitis B antigen result.
Expert insights. Personalized for you.
69 
Let's personalize your content